Corporate Profile

Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is an anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody in development for thyroid eye disease (TED), a debilitating auto-immune disease that causes inflammation and fibrosis of the orbital tissues surrounding the eye, leading to proptosis, or bulging of the eyes, redness and swelling, diplopia (double vision), pain, and potential blindness. Current treatments options remain limited and burdensome. In August 2022, the Company announced positive initial clinical data from ongoing Phase 1/2 Trial evaluating VRDN-001 in patients with TED - access the August news release and data deck. In November 2022, Viridian reported positive clinical data for 10 mg/kg and 20 mg/kg – access the November news release and data deck.

The Company is based in Waltham, Massachusetts, with offices in Boulder and New York City.

Stock Information

Viridian Therapeutics (NASDAQ - VRDN)

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Corporate Presentation

December 1, 2022
Viridian Therapeutics Corporate Overview – December 2022
Download PDF